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Abstract
Purpose One key aim of Phase I cancer studies is to
identify the dose of a treatment to be further evaluated in
Phase II. We describe, in non-statistical language, three
classes of dose-escalation trial design and compare their
properties.
Methods We review three classes of dose-escalation
design suitable for Phase I cancer trials: algorithmic
approaches (including the popular 3 ? 3 design), Bayesian
model-based designs and Bayesian curve-free methods. We
describe an example from each class and summarize the
advantages and disadvantages of the design classes.
Results The main benefit of algorithmic approaches is the
simplicity with which they may be communicated: it may
be for this reason alone that they are still employed in the
vast majority of Phase I trials. Model-based and curve-free
Bayesian approaches are preferable to algorithmic methods
due to their superior ability to identify the dose with the
desired toxicity rate and their allocation of a greater pro-
portion of patients to doses at, or close to, that dose.
Conclusions For statistical and practical reasons, algo-
rithmic methods cannot be recommended. The choice
between a Bayesian model-based or curve-free approach
depends on the previous information available about the
compound under investigation. If this provides assurance
about a particular model form, the model-based approach
would be appropriate; if not, the curve-free method would
be preferable.
Keywords 3 ? 3 design  Bayesian method  Clinical
trial, Phase I  Continual reassessment method  CRM 
Curve free
Introduction
Ethical considerations [1] require the use of efficient trial
designs in order to optimize the balance of risk versus
benefit for participants. In Phase I cancer studies, this would
include minimizing the numbers of patients allocated to
ineffective or excessively toxic doses, while addressing the
principal aim of identifying the best dose of a treatment to
recommend for further evaluation in a Phase II trial. In this
article, we focus on the identification of the maximum
tolerated dose (MTD), which remains a key factor in this
decision. In practice, additional aspects such as the bio-
logical level of anti-cancer activity of a dose would also be
considered. The 3 ? 3 trial design [2, 3], which has been
widely implemented, has substantial limitations: we
describe two alternative classes of dose-escalation strategy,
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using specific examples [4–6] drawn from the many designs
available to illustrate their superiority to the 3 ? 3 design
on several relevant study design criteria.
Phase I studies play an extremely important role in the
development of a cancer treatment as the agent is often
given to humans for the first time. As a result, conservative
approaches that tend to start at doses much lower than the
anticipated highest safe dose and slowly approach the dose
of interest from below are usually employed. The popula-
tion studied is not necessarily the population to be treated
and the questions are many despite the subjects being few.
Consequently much uncertainty about dose, safety and
efficacy will remain afterward. These studies are, however,
critical to successful drug development as the decision on
whether to continue and the design of any subsequent trials
depend on the outcome of this first study.
Phase I dose-escalation studies in cancer traditionally
enroll late stage patients for whom other therapies have
failed. Due to the narrow therapeutic index of cytotoxic
drugs and the variable toxicities that may occur at the
therapeutic dose of newer targeted anti-cancer drugs, the
MTD has been considered a reasonable basis on which to
determine an appropriate dose for further clinical use.
Hence, in addition to investigating the pharmacokinetics,
toxicities and biological activity of a drug, Phase I cancer
studies aim to find the MTD, the highest dose that can safely
be administered. More precisely, one seeks the dose that has
an acceptable risk of dose-limiting toxicity (DLT). In this
context, a DLT is a serious adverse event that impairs usual
activities and requires therapeutic intervention [7–9]. Late
toxicities or lower graded, cumulative or additive toxicities
that do not individually meet the DLT criteria also contain
information on the safety and activity of a drug; however,
the designs used to date do not take account of such events
[10]. Advances in this area would clearly have potential to
enhance decision making at the end of Phase I.
Commonly the dose at which the probability of a DLT is
p (for 0 \p\ 1) is called the TD100p. For example, the
TD25 would refer to the dose associated with a 25 %
toxicity risk. The rationale for seeking the TD100p is to
ensure a safe dose is identified for further study and is
based on the common assumption, specifically for cyto-
toxic compounds, that efficacy increases with toxicity. The
latter implies that finding the highest tolerable dose will
ensure that the most efficacious dose is investigated sub-
sequently. First, cycle toxicity is a critical and immediate
measure that can guide the decision on whether the dose
may be escalated safely, and the use of this rather than later
efficacy outcomes ensures minimal trial duration.
A key ingredient of any dose-escalation study is the set
of doses to be explored. Figure 1 illustrates four different
dose schedules for a given, hypothetical, dose–toxicity
relationship. Each graph depicts dose versus toxicity risk
and assumes an increasing relationship between them. The
arrows indicate the doses available and it is assumed that a
toxicity risk of 25 % is acceptable. Figure 1a has very low
risk of toxicity for the lower two doses while the upper two
doses have a toxicity risk close to 100 %. Such a dose
schedule therefore only allows the conclusion that the
TD25 lies somewhere between the middle two doses;
neither of the doses available is, however, close to the
desired toxicity risk. In Fig. 1b, all the doses lie above the
desired toxicity level. In this situation, not only does none
of the doses have an acceptable toxicity risk, but we cannot
even be sure that any dose of the compound is safe. Sim-
ilarly, if all doses were below the desired TD25, we would
not know if any dose corresponded to the TD25 and hence
whether a biologically active dose had been attained.
Figure 1c shows the advantage of allowing many differ-
ent doses. It is clear that such a dose schedule allows much
more accurate TD25 estimation as the interval between doses
is much smaller. While adding doses to allow for more
accurate estimation is appealing, doing so requires a differ-
ent dose-escalation strategy to the commonly employed
methods in order to limit the sample size and avoid many
patients receiving doses well below those expected to have
either toxicity or efficacy. Figure 1d represents an ideal sit-
uation where many doses are available, but excessively toxic
or ineffective doses represented by lighter shaded arrows are
explored less often or possibly even skipped altogether.
Traditionally, dose escalation starts at a low dose
defined preclinically and slowly escalates dose in
decreasing increments according to a predetermined strat-
egy (the modified Fibonacci sequence, in which the dose
increments for succeeding dose levels are 100, 67, 50,
40 % then 33 % for all subsequent levels [11]). Alternative
escalation strategies [12] include accelerated titration
designs [3], pharmacokinetically guided dose escalation
[13] and continual reassessment or Bayesian methods [4,
14–16] which have been successfully incorporated into
Phase I trial design [17, 18].
From here on, we assume that a sensible selection of
doses is available but stress that inclusion of more potential
doses within the range of interest may allow more accurate
estimation of the highest tolerable dose. To avoid ‘‘wast-
ing’’ patients at doses that are no longer of interest based on
the data gathered so far in the trial, skipping doses [6] or
the use of single patients at early dose levels [3] could be
considered.
There exists a vast literature on dose-escalation methods
for Phase I trials in cancer, yet very few of them have been
used in practice. By far the most popular approach to dose
escalation is the 3 ? 3 design [2] which, according to Le
Tourneau et al. [12], was used in 96.7 % of Phase I trials
published in 2007 and 2008. A similar finding was made by
Rogatko et al. [19] when they investigated the use of
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Bayesian designs in Phase I cancer trials. Only 20 (1.6 %)
of 1,235 trials followed a Bayesian design despite the
existence of around 100 publications demonstrating the
statistical properties of such designs.
There are three general approaches to dose finding
studies in cancer. We will introduce their main features and
compare their advantages and disadvantages. In particular,
we will show that the most popular design in practice has




Rule-based dose-escalation methods include the Storer up-
and-down design [3] and the frequently applied 3 ? 3
design (Fig. 2). Although several variants of this long-
established approach have been published, the earliest
source is a book chapter arising from the proceedings of a
clinical pharmacology course held in Brussels in May 1972
[2]. The main principle of algorithmic designs is that a
small group of patients is treated at a given dose and,
dependent on the observed number of toxicities, a decision
is made on to whether to study a further group of patients at
the next dose up the scale, to study more patients at the
same dose or to stop the trial.
The 3 ? 3 design, for example, enters three patients into
the trial one at a time at intervals of seven days or more and
treats them at the chosen starting dose. The core features of
this design, as outlined by Storer [3], are:
(a) If no dose-limiting toxicity (DLT) occurs in the first
cycle of any of the initial group of 3 patients treated at
a dose, the dose should be escalated for the next group
of patients.
(b) If two or more of the 3 patients treated at a given dose
experience a DLT, the trial should stop.
(c) If one patient of the 3 treated at a given dose level

























































Fig. 1 Schematic illustration of different problems in finding the
TD25, the dose at which the underlying risk of dose-limiting toxicity
is 25 %. a Four doses, none of which matches the target toxicity rate;
(b) six doses, all lying above the desired toxicity level; (c) many
doses, allowing accurate estimation of the TD25; (d) many doses,
with increased efficiency through less frequent use of excessively
toxic or ineffective doses
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the same dose level. If a DLT has occurred in exactly
one of these 6 patients, escalation may continue as in
(a); otherwise, the trial should stop.
A frequent variation allows the dose to be reduced if
more than one DLT is observed within the first three
patients studied at a particular dose.
Following completion of the trial according to this
design, the MTD is defined as either the actual dose at
which the trial was stopped or the next lower dose, possibly
depending on the frequency and severity of toxicity
observed in the patients evaluated in the final group [3]. A
number of adaptations of this design attempt to reduce the
number of patients treated at the lowest dose levels [20].
Such accelerated titration designs [18, 21] include single-
patient dose levels and more rapid dose escalation (e.g.,
dose doubling) until the first DLT is observed, after which
the dose-escalation scheme would then revert to the mod-
ified Fibonacci sequence.
Model-based Bayesian methods
Bayesian modeling combines prior knowledge of the drug
with the observed data from the current trial to provide
updated information about the distribution of the trial
outcome of interest. Bayesian methods have been incor-
porated into a number of early phase clinical trial designs,
the best known being the continual reassessment method
(CRM) [4, 5]. In contrast to the algorithmic approach of the
3 ? 3 design, the continual reassessment method aims to
identify the dose at which the proportion of patients
experiencing a DLT reaches a specific target level (e.g.,
25 %). Furthermore, the investigator performs repeated
analyses on all of the data gathered to date—hence the term
continual reassessment—rather than simply observing the
data recorded at the current dose, as is the case for the
3 ? 3 design.
The CRM uses a one-parameter Bayesian model which
assumes that the probability of toxic response increases
with dose: as we move from one dose up to the next
higher dose, the toxicity risk at the higher dose is greater
than or equal to that at the previous dose. Before the trial
has commenced, Bayesian modeling requires a prior dis-
tribution for the dose–toxicity curve parameters to be
specified [22], representing the expected shape of the
dose–toxicity relationship. In the original version of the
CRM, a simple one-parameter prior distribution is rec-
ommended; subsequent developments allow the prior to
be informed by data (such as information from pre-clin-
ical studies) or expert opinion (see for example [23] for
alternatives). The model may be updated as soon as new
data become available on previously included patients.
Following this the next patient, or group of patients, is
treated at the dose, based on the evidence to date, that has
an estimated probability of toxicity closest to the target
level.
New cohort at new dose 
level: Enrol 3 patients 
Go to next higher dose 
level or same dose 
level if already at 
highest dose level 
Enrol 3 additional 
patients at the same 
dose level 
Go to next lower dose 
level or declare MTD at 
next lower dose level if 6 
patients already tested 
there
Go to next higher dose 
level or declare MTD 
otherwise 
Go to next lower dose 
level or declare MTD 
at next lower dose 
level if 6 patients 
already tested there 
DLT=1/3 DLT>1/3DLT=0/3
DLT=1/6 DLT>1/6
Fig. 2 Schematic display of
one version of the 3 ? 3 design
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Once all patients have been treated and followed up, the
MTD is taken to be the dose at which the estimated toxicity
probability is closest to the target level. Although the
originally proposed CRM method allows for the initial
dose to be above the lowest available dose level, in prac-
tice, a modified version that enforces dose escalation to
start from the lowest dose [24] is usually employed.
Stopping rules have been developed for the CRM [25] to
allow early discontinuation of the trial in the situation
where all doses are found to be excessively toxic.
Alternative Bayesian model-based approaches include
escalation with overdose control (EWOC) designs [16] and
the TITE-CRM extension of the CRM which allows the
trial to be completed more quickly by incorporating time to
toxicity event data [26].
Curve-free Bayesian approaches
This class of escalation strategies includes work by
Gasparini and Eisele [27] and Whitehead et al. [6] and aims
to minimize the number of assumptions within the dose–
toxicity modeling. No assumption is made about the form
of the relationship between dose and toxicity except that, as
in the CRM, the probability of toxic response increases
with dose. The risk of toxicity is modeled directly, result-
ing in an easy to interpret table of probabilities for each
risk level.
The possible levels of toxicity risk at a dose are described
qualitatively as very safe, safe, ideal, risky or toxic. The
numerical probability value that corresponds to each of
these descriptors depends on the target toxicity level. The
‘‘ideal’’ risk category has exactly the target toxicity prob-
ability, while the ‘‘safe’’ and ‘‘very safe’’ categories have
progressively lower risks of toxicity and the ‘‘risky’’ and
‘‘toxic’’ categories have progressively higher risks. For
example, in a study aiming to identify the dose which has
toxicity rate 25 %, the descriptors very safe, safe, ideal,
risky and toxic might be assigned the probability values
0.05, 0.15, 0.25, 0.4 and 0.65, respectively.
The prior distribution summarizing previous knowl-
edge of the expected risk at each dose level, required
under the Bayesian framework, is informed by investi-
gator opinion. As data accumulate during the trial, the
updated probabilities of each risk level being associated
with each dose are calculated. The dose to be allocated to
the next patient enrolled in the trial is selected to avoid
doses that have anything other than a small chance of
being ‘‘toxic’’ and to target the dose that has the greatest
chance of being ‘‘ideal’’. Table 1 illustrates the proba-
bilities of each level of toxicity during a hypothetical
trial. Here, 25 % is the target toxicity rate, and dose level
7 is the one with the highest probability of having that
toxicity rate.
At the end of the trial, one of three approaches may be
used to determine which dose to take forward for further
study. The first method bases the decision on the final table
of updated risk level probabilities. If the dose with a tox-
icity risk of 25 % was being sought, then the dose with the
highest probability of having a toxicity risk of 25 % would
be recommended. In the second, perhaps more realistic,
strategy, the table of updated risk level probabilities would
form just part of the information being considered by
investigators when deciding what dose to recommend. The
complete study data set will contain far more information
than DLT occurrences: pharmacokinetic and clinical data
and the expert opinion of investigators could also inform
the recommendation. The third approach would be to take
the data set and apply any appropriate method of statistical
analysis, independently of the dose allocation method used
in the trial.
Discussion
The merits and shortcomings of the three classes of dose-
escalation procedures introduced above will now be dis-
cussed. A broad range of important criteria, including
statistical and practical aspects, to consider when evaluat-
ing a dose-escalation procedure will be considered under
five headings. The weighting for each of the criteria will
depend on the specific trial and consequently it is unlikely
that each point will carry equal weight across all trials. We
have summarized this in Table 2 where we have graded the
performance of the dose-escalation procedure for each item
under the five headings qualitatively as poor, intermediate,
good or not applicable.
Statistical properties
We expect a good statistical procedure to estimate a spe-
cific measure of toxicity and that the precision of this
estimate can be gauged. Moreover, we want additional
information (i.e., additional patients) to increase the pre-
cision in the estimate. Both the model-based and curve-free
approach aim to estimate a clear cut measure of toxicity:
the dose at which a certain proportion of patients is
expected to experience a toxic event. Both methods also
quantify the precision of the estimated dose and this pre-
cision increases as the sample size increases: they have
good statistical properties. Furthermore, were complete
information to be available on toxicity of every dose for
each patient, the CRM model-based design has perfor-
mance very close to that of the best design that could exist
theoretically [28].
The algorithmic approach, in contrast, tries to find the
MTD which is difficult to quantify. As a consequence of
Cancer Chemother Pharmacol (2013) 71:1107–1114 1111
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this loose definition, it is also impossible to obtain a
measure of precision for the MTD. Furthermore, the
algorithmic nature of the method means that additional data
do not feature in the estimated MTD and the decision about
whether a dose is the MTD only depends on what has been
observed at this dose level: no learning from the doses
above or below is possible. Consequently, algorithmic
approaches have very poor statistical properties: the 3 ? 3
design correctly identifies the dose with toxicity rate
closest to the target level less frequently than model-based
designs [29] and over the course of the trial exposes many
additional patients to doses above or below that optimal
dose. Only 35 % of patients are treated at the optimal dose
with the 3 ? 3 design compared to 55 % for Bayesian
adaptive designs [19].
We gain insight into this poor performance of the
algorithmic design by quantifying the evidence when one
out of a group of three patients has experienced a DLT: the
95 % confidence interval (CI) around the best estimate of
33 % for the toxicity rate ranges from 0.8 to 90.6 %,
illustrating that little has been learned about the true rate.
There is not substantially more evidence even when two of
six patients studied at a dose experience a DLT: the cor-
responding 95 % CI for the toxicity rate is (4.3, 77.7 %).
Simplicity
The ideal method would be easy to describe to clinicians
and be straightforward statistically. The latter criterion
does not apply to the algorithmic approach as it is not a
statistically derived method. It is, however, the simplest to
explain to non-statisticians and may be used without the
involvement of a statistician. The Bayesian model-based
approach is of moderate statistical complexity, but is easily
implemented in practice, in part due to software being
readily available (e.g., the R package CRM [30]). A par-
ticular challenge that does remain is specifying the prior
distributions, which we believe is best done in consultation
Table 1 Example of risk level
probabilities generated by the
Bayesian curve-free approach
Bold value indicates the dose
level with the highest
probability of having the
‘‘ideal’’ toxicity rate
Dose level Risk of toxicity
5 % ‘‘very safe’’ 15 % ‘‘safe’’ 25 % ‘‘ideal’’ 40 % ‘‘risky’’ 65 % ‘‘toxic’’
1 0.48 0.44 0.08 0.00 0.00
2 0.40 0.48 0.12 0.00 0.00
3 0.33 0.52 0.15 0.00 0.00
4 0.25 0.55 0.19 0.01 0.00
5 0.17 0.54 0.28 0.01 0.00
6 0.08 0.49 0.40 0.03 0.00
7 0.01 0.28 0.61 0.10 0.00
8 0.01 0.14 0.40 0.33 0.12
9 0.01 0.05 0.19 0.40 0.35
Table 2 Characteristics of dose-escalation strategies
Issues to consider Algorithmic Model based Curve free
1. Statistical properties
1a Does method provide estimate of a relevant parameter and allow
the precision of the estimate to be quantified?
Poor Good Good
1b Does precision increase with sample size? Poor Good Good
1c Reliably arrives at correct decision on dose with target toxicity risk Poor Good Good
2. Simplicity
2a Non-technical explanation of method Good Poor Intermediate
2b Statistical complexity Not applicable Intermediate Poor
3. Intuitive dose recommendations Good Intermediate Good
4. Flexibility
4a Target toxicity rate Poor Good Good
4b Accommodating underlying shape of dose–response Poor Good Good
4c Dose skipping Poor Good Good
5. Impact of number of doses in schedule Poor Good Good
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with a statistician. Finally, the curve-free Bayesian method
is relatively simple to explain to non-statisticians (though
much more complex than the 3 ? 3 design) as it directly
estimates the risk of each dose rather than using a specific
model. The price for this conceptual simplicity is a much
more involved statistical process.
The contrast between the model-based and the curve-
free approaches is that the former requires the dose–tox-
icity model to be specified in advance of the study through
discussion between the clinicians and a statistician. Nev-
ertheless, it can still consistently identify the dose that has
the desired toxicity rate, even when the model has been
misspecified [4, 31]. The curve-free approach only assumes
non-decreasing risk of toxicity as dose increases. Although
this assumption is often reasonable, the curve-free
approach depends on it while a model-based approach
could allow for decreases in toxicity risk provided that this
was specified in the model.
Intuitive dose recommendations
The optimal dose-escalation method would recommend
doses for subsequent patients or for Phase II trials with
which an experienced investigator would be comfortable.
In general, all three approaches perform well although it
does depend on the exact implementation: the originally
proposed CRM [4] does sometimes give a counterintuitive
dose recommendation [23] but subsequent modifications
have been developed [24] to overcome this.
Flexibility
In particular, we are interested whether any target toxicity
rate can be used, how robust the method is to variations in
the true dose–toxicity relationship and whether the method
can skip doses. The algorithmic approach fairs poorly on
all three counts. In its design, the MTD rather than a certain
toxicity rate is sought, while dose skipping is prohibited.
The dose recommendation only depends on the current
dose and hence the underlying dose–toxicity relationship is
not exploited. The model-based approach on the other hand
caters for any toxicity level and, depending on the exact
implementation, can allow dose skipping. In addition, any
model can be used although it is clear that specifying the
correct model before starting the study will sometimes be
difficult. As an alternative to modeling the dose–toxicity
relationship, the model-based approach may also be used in
a continual reassessment of pharmacokinetic data [13, 18],
pharmacodynamic data [32, 33] or toxicity and efficacy
data in combination [34]. The Bayesian curve-free
approach may also be applied to combined toxicity and
efficacy data [35] (and indeed pharmacodynamic data) if
these are binary. As well as allowing any target toxicity
rate and dose skipping, the biggest advantage of the curve-
free approach is that it is suitable for any underlying dose–
toxicity relationship provided toxicity increases with dose.
This implies that, unlike the model-based approach, the
form of the relationship does not have to be specified in
advance. Both the model-based and Bayesian curve-free
approaches permit single-patient dose cohorts, which can
dramatically improve the trial design efficiency.
Impact of number of doses in schedule
As illustrated in Fig. 1c, a large number of doses allow
more precise estimation of the dose of interest although it
potentially comes at a price of many patients being treated
at sub-optimal doses. With the algorithmic approach, the
decision about a dose only depends on what has been
observed at this dose level: it does not make use of the
information from any of the previous dose levels. In con-
sequence, a large number of doses increase the chance of
selecting too safe a dose as even a very safe dose may
result in two out of six patients having a DLT [as noted
above, the toxicity rate confidence interval in that scenario
would be (4.3, 77.7)]. The situation is exacerbated by
disallowing skipping of doses and thereby enforcing
assessment of every dose incrementally. In contrast, both
the model-based and curve-free methods allow dose skip-
ping and use data from all patients in estimating risk of
toxicity at each dose level, and so perform well when many
doses are available.
Conclusion
Overall the main benefit of the algorithmic approach is the
simplicity of communicating the method and incorporating
it into trial protocols and it may be for this reason alone
that it is still employed in the vast majority of Phase I trial
designs. On the grounds of statistical and other practical
considerations, however, it cannot be recommended. The
model-based and curve-free approaches have similar merits
and are preferable to algorithmic methods due to their
superior ability to identify the dose with the desired tox-
icity rate. Although it is desirable to involve a statistician in
the planning of a Phase I oncology trial, Bayesian model-
based methods can readily be implemented by a numerate
scientist or clinician. The decision whether a model-based
approach is to be used will largely depend on the previous
information available about the compound under investi-
gation. Substantial evidence from preclinical studies or
studies in different indications regarding the shape of the
dose–response curve would motivate use of the model-
based approach over the curve-free method. If there is
sufficient evidence of high enough quality from previous
Cancer Chemother Pharmacol (2013) 71:1107–1114 1113
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studies, the model-based approach will be slightly superior
to the curve-free one, but if not, resulting in the wrong
model, it will perform less well.
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